A roundup of mergers & acquisitions from Sanofi and Ipsen.

Sanofi Completes $1.2-Bn Acquisition of Amunix
Sanofi has completed acquisition of Amunix Pharmaceuticals, an immuno-oncology company, in a deal worth up to $1.2-billion ($1 billion at closing plus $225 million in milestones)

Amunix is developing masked T cell engagers (TCE) and cytokines, which are designed to preferentially activate in the tumor microenvironment and to overcome toxicity challenges of other T cell and cytokine therapies. Amunix’s proprietary masking technology has been clinically validated to extend drug half-life with limited immunogenicity. The company’s initial product candidate is AMX-818, a T cell engager targeting a variety of HER2-expressing solid tumors.

The acquisition also provides access to Amunix’s proprietary Pro-XTEN, XPAT, and XPAC technology to deliver conditionally activated biologics.

Under the agreement, Sanofi acquired Amunix for an upfront payment of approximately $1 billion and up to $225 million upon achievement of certain future development milestones.

Source: Sanofi

---

Ipsen To Divest Consumer Healthcare Business
Ipsen, a Paris-based bio/pharmaceutical company, has entered into exclusive negotiations with Mayoly Spindler, a Chatou, France-based bio/pharmaceutical company, for sale of Ispen’s global consumer healthcare business (CHC), for a total enterprise value of EUR 350 million ($395 million).

The consideration for Ipsen’s CHC business represents an enterprise value of EUR 350 million ($395 million), including an earnout contingent payment of EUR 50 million ($57 million).

The proposed transaction will be submitted to the relevant employee-representation bodies and is expected to close before the end of the third quarter of 2022, subject to regulatory approvals and customary closing conditions.

Source: Ipsen